RESMED INC
Financial highlights
| Metric | FY June 30, 2025 | FY June 30, 2024 | FY June 30, 2023 | FY June 30, 2022 | FY June 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.1B | $4.7B | $4.2B | $3.6B | $3.2B |
| Gross profit | $3.1B | $2.7B | $2.4B | $2.0B | $1.8B |
| Operating income | $1.7B | $1.3B | $1.1B | $1.0B | $903.7M |
| Operating expenses | $1.4B | $1.3B | $1.2B | $1.0B | $935.4M |
| Cost of revenue | $2.1B | $2.0B | $1.9B | $1.6B | $1.4B |
| Cash from operations | $1.8B | $1.4B | $693.3M | $351.1M | $736.7M |
| Capital expenditure | $89.9M | $99.5M | $119.7M | $134.8M | $102.7M |
| Free cash flow | $1.7B | $1.3B | $573.6M | $216.3M | $634.0M |
| Share repurchases | $300.0M | $150.0M | $0 | $0 | — |
| Impairments | — | — | $0 | $0 | $0 |
| Total assets | $8.2B | $6.9B | $6.8B | $5.1B | $4.7B |
| Total liabilities | $2.2B | $2.0B | $2.6B | $1.7B | $1.8B |
| Total debt | $668.3M | $707.2M | $1.4B | $775.2M | $655.4M |
Shares outstanding 145.1M · Free float 94.9%
Annual filing data through FY ended June 30, 2025; float as of July 11, 2026.
Recent filings
- July 7, 2026 8-K
- May 1, 2026 10-Q
- April 30, 2026 8-K
- April 30, 2026 8-K
- January 30, 2026 10-Q
- January 29, 2026 8-K
- November 20, 2025 8-K
- October 31, 2025 10-Q